Cai, Ming-Ci
Cheng, Shu
Wang, Xin
Hu, Jian-Da
Song, Yong-Ping
Huang, Yao-Hui
Yan, Zi-Xun
Jiang, Yu-Jie
Fang, Xiao-Sheng
Zheng, Xiao-Yun
Dong, Li-Hua
Ji, Meng-Meng
Wang, Li
Xu, Peng-Peng
Zhao, Wei-Li
Funding for this research was provided by:
National Natural Science Foundation of China (81520108003, 81830007, 81670176, 81700191)
Science and Technology Commission of Shanghai Municipality (16JC1405800)
Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant Support (20152206)
Science and Technology Commission of Shanghai Municipality (20152208)
Shanghai Shen Kang Hospital Development Center (16CR2017A)
School of Medicine, Shanghai Jiao Tong University (DLY201601)
Collaborative Innovation Center for Systems Biomedicine (/)
Samuel Waxman Cancer Research Foundation (/)
Multicenter Hematology-Oncology Programs Evaluation System (/)
Article History
Received: 1 October 2019
Accepted: 10 April 2020
First Online: 30 April 2020
Ethics approval and consent to participate
: The study was approved by the ethics committee on May 11, 2015, in Shandong Province Hospital Ethics Committee (No. 2015-10), registered and approved by the clinicaltrial.gov. on August 27, 2015. The study was also approved by the Institutional Review Boards of the other participating study centers: Shanghai Rui Jin Hospital, Fujian Medical University Union Hospital, and the Affiliated Cancer Hospital of Zhengzhou University. The first patient was enrolled in September 22, 2015. Informed consent was obtained from all patients prior to enrollment and the study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.